Tengion Inc. Files $40.25 Million IPO

EAST NORRITON, Pa.--(BUSINESS WIRE)--Tengion Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range of the offering have not yet been determined.

Piper Jaffray & Co. is acting as the sole manager.

A registration statement relating to the common stock has been filed with the SEC but has not yet become effective. The common stock may not be sold, nor may offers to buy be accepted prior to the time the registration statement becomes effective. The registration statement may be accessed through the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

This offering shall be made only by means of a prospectus. Once available, a preliminary prospectus relating to these securities may be obtained from Piper Jaffray & Co. at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402 or by calling (800) 747-3924.

About Tengion

Tengion is a clinical-stage company focused on discovering, developing, manufacturing and commercializing a range of replacement organs and tissues, or neo-organs and neo-tissues. These functional neo-organs and neo-tissues are currently created using a patient’s own cells, or autologous cells, in conjunction with the company’s Organ Regeneration Platform.

Contact:

Tengion Inc. Mark Stejbach, 267-960-4884 Chief Commercial Officer mark.stejbach@tengion.com